Apr 01, 2025 7:00am EDT Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31, 2025 7:00am EDT Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
Mar 13, 2025 7:00am EDT Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
Feb 20, 2025 7:00am EST Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
Jan 28, 2025 7:00am EST Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Jan 07, 2025 7:00am EST Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
Dec 17, 2024 7:00am EST Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
Nov 21, 2024 7:00am EST Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Nov 13, 2024 7:15am EST Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Nov 11, 2024 7:00am EST Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
